Nivolumab 100mg Injection, marketed under the brand name Opdivo, is an immunotherapy medication used to treat various types of cancer, including melanoma, non-small cell lung cancer (NSCLC), kidney cancer, and more. It functions as a checkpoint inhibitor, blocking the PD-1 receptor to enhance the body’s immune response against cancer cells.
Indications: Nivolumab 100mg Injection is approved for the treatment of several cancers, either as a monotherapy or in combination with other therapies:
- Melanoma: Treatment of unresectable or metastatic melanoma.
- Non-Small Cell Lung Cancer (NSCLC): Treatment of metastatic NSCLC with progression on or after platinum-based chemotherapy.
- Renal Cell Carcinoma (RCC): Treatment of advanced RCC after prior therapy.
- Head and Neck Cancer: Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based therapy.
- Classical Hodgkin Lymphoma (cHL): Treatment of cHL that has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin, or after three or more lines of systemic therapy that includes autologous HSCT.
- Urothelial Carcinoma: Treatment of locally advanced or metastatic urothelial carcinoma with disease progression during or following platinum-containing chemotherapy.
- Colorectal Cancer: Treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
- Esophageal Squamous Cell Carcinoma (ESCC): Treatment of unresectable advanced, recurrent, or metastatic ESCC after prior chemotherapy.
- Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma: Treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
- Adjuvant Treatment of Resected Esophageal or Gastroesophageal Junction Cancer: Treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy.
mechanism of action of Nivolumab 100mg injection
- Dosage and Administration: The recommended dosage of nivolumab varies based on the specific cancer being treated:
- Monotherapy: 3 mg/kg administered as an intravenous infusion over 60 minutes every 2 weeks, or 240 mg every 2 weeks, or 480 mg every 4 weeks.
- Combination Therapy: Dosing schedules may differ when nivolumab is used in combination with other therapies.
- Treatment should be continued until disease progression or unacceptable toxicity occurs.Side Effects: Common side effects of Nivolumab 100mg Injection include:
- Fatigue
- Rash
- Musculoskeletal pain
- Pruritus (itching)
- Diarrhea
- Nausea
- Cough
- Shortness of breath
- Decreased appetite
- Back pain
- Joint pain
- Upper respiratory tract infection
- Fever
- Headache
- Abdominal pain
- Vomiting
Serious side effects can occur, including immune-mediated adverse reactions affecting various organs. Patients should be monitored for signs and symptoms of these reactions.
Availability: Nivolumab is available in various dosages, including 100 mg/10 mL (10 mg/mL) for intravenous infusion. It is supplied in single-dose vials; any unused portion should be discarded
Important Considerations:
- Nivolumab is administered intravenously and should be given under the supervision of a healthcare professional experienced in the use of cancer therapies.
- Patients should be evaluated for immune-mediated adverse reactions and managed accordingly.
- Use during pregnancy may harm the baby; women should be advised of potential risks.
For more detailed information, including comprehensive prescribing information, please refer to the official prescribing information provided by the manufacturer.
Website: Jyotilifecar